{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:50:24Z","timestamp":1777431024944,"version":"3.51.4"},"reference-count":72,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Disease-modifying therapies (DMTs) are the standard treatment for multiple sclerosis (MS) and effectively reduce inflammatory disease activity; however, their effects on neurodegeneration, remyelination failure, and long-term symptom burden vary across disease stages and patient populations. Adjunctive non-DMT approaches have therefore been investigated to target biological processes not primarily addressed by conventional immunomodulatory treatment. These strategies often involve agents originally developed for non-neurological indications, whose mechanisms of action extend beyond their primary clinical use and may intersect with pathways relevant to MS pathophysiology. This narrative review summarizes pharmacological agents, nutraceuticals, and selected bioactive compounds evaluated as adjunctive interventions in MS, with emphasis on immunometabolic regulation and remyelination-related mechanisms. Evidence from experimental models, translational studies, and clinical trials is examined to assess repurposed drugs and metabolic modulators with reported effects on immune responses, glial function, and myelin repair. Particular emphasis is placed on the distinction between mechanistic rationale and clinical outcomes, highlighting the challenges of translating biologically plausible effects into consistent therapeutic benefit. Available data indicate that most adjunctive strategies do not demonstrate consistent disease-modifying effects, although some interventions influence specific biological pathways relevant to neuroinflammation, cellular metabolism, and oligodendrocyte biology. Reported outcomes vary according to disease stage, treatment duration, and selected clinical or imaging endpoints. Overall, adjunctive non-DMT strategies remain investigational and require further evaluation in biologically stratified clinical studies.<\/jats:p>","DOI":"10.3390\/ijms27093857","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:33:37Z","timestamp":1777376017000},"page":"3857","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjunctive Non-Disease-Modifying Therapies in Multiple Sclerosis: Immunometabolic, Neuroprotective and Remyelination-Oriented Approaches"],"prefix":"10.3390","volume":"27","author":[{"given":"Agnieszka","family":"Damiza-Detmer","sequence":"first","affiliation":[{"name":"Department of Neurology and Stroke, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1305-1494","authenticated-orcid":false,"given":"Andrzej","family":"G\u0142\u0105bi\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Neurology and Stroke, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"Montalban","year":"2025","journal-title":"Lancet Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nrn.2017.136","article-title":"Regenerating CNS myelin\u2014From mechanisms to experimental medicines","volume":"18","author":"Franklin","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1474-4422(20)30140-X","article-title":"Remyelination in multiple sclerosis: From basic science to clinical translation","volume":"19","author":"Lubetzki","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/S0140-6736(25)01039-6","article-title":"Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"406","author":"Chataway","year":"2025","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Schreiner, T.G., Romanescu, C., and Popescu, B.O. (2022). The Blood-Brain Barrier\u2014A Key Player in Multiple Sclerosis Disease Mechanisms. Biomolecules, 12.","DOI":"10.3390\/biom12040538"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1474-4422(23)00377-0","article-title":"Blood-brain barrier dysfunction in multiple sclerosis: Causes, consequences, and potential effects of therapies","volume":"23","author":"Zierfuss","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"fcae109","DOI":"10.1093\/braincomms\/fcae109","article-title":"Age-dependent effects of metformin on human oligodendrocyte lineage cell ensheathment capacity","volume":"6","author":"Mohammadnia","year":"2024","journal-title":"Brain Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.stem.2019.08.015","article-title":"Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells","volume":"25","author":"Neumann","year":"2019","journal-title":"Cell Stem Cell"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kruczkowska, W., Ga\u0142\u0119ziewska, J., Buczek, P., P\u0142uciennik, E., Kciuk, M., and \u015aliwi\u0144ska, A. (2025). Overview of Metformin and Neurodegeneration: A Comprehensive Review. Pharmaceuticals, 18.","DOI":"10.3390\/ph18040486"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"105943","DOI":"10.1016\/j.msard.2024.105943","article-title":"Comorbidities and their association with outcomes in the multiple sclerosis population: A rapid review","volume":"92","author":"Frank","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Marrie, R.A., Fisk, J.D., Fitzgerald, K., Kowalec, K., Maxwell, C., Rotstein, D., Salter, A., and Tremlett, H. (2023). Etiology, effects and management of comorbidities in multiple sclerosis: Recent advances. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1197195"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40263-015-0239-x","article-title":"Statin treatment in multiple sclerosis: A systematic review and meta-analysis","volume":"29","author":"Tsakiri","year":"2015","journal-title":"CNS Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.expneurol.2017.08.013","article-title":"AMPK activation: Role in the signaling pathways of neuroinflammation and neurodegeneration","volume":"298","author":"Peixoto","year":"2017","journal-title":"Exp. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1084\/jem.20151570","article-title":"Immunometabolism governs dendritic cell and macrophage function","volume":"213","author":"Pearce","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Reed, S., Taka, E., Darling-Reed, S., and Soliman, K.F.A. (2025). Neuroprotective Effects of Metformin Through the Modulation of Neuroinflammation and Oxidative Stress. Cells, 14.","DOI":"10.3390\/cells14141064"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s12035-014-8647-3","article-title":"Statins and Neuroprotection: Basic Pharmacology Needed","volume":"50","author":"Wood","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature01158","article-title":"The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease","volume":"420","author":"Youssef","year":"2002","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1186\/s12967-024-05436-9","article-title":"Metformin enhances endogenous neural stem cells proliferation, neuronal differentiation, and inhibits ferroptosis through activating AMPK pathway after spinal cord injury","volume":"22","author":"Xing","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Dziedzic, A., Saluk-Bijak, J., Miller, E., and Bijak, M. (2020). Metformin as a potential agent in the treatment of multiple sclerosis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21175957"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ana.10206","article-title":"Peroxisome proliferator-activated receptor-\u03b3 agonists prevent experimental autoimmune encephalomyelitis","volume":"51","author":"Feinstein","year":"2002","journal-title":"Ann. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"108226","DOI":"10.1016\/j.bioorg.2025.108226","article-title":"Peroxisome proliferator-activated receptors (PPARs) agonists as promising neurotherapeutics","volume":"156","author":"Ghannam","year":"2025","journal-title":"Bioorganic Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/89058","article-title":"Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site","volume":"7","author":"Welzenbach","year":"2001","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/glia.20441","article-title":"Simvastatin regulates oligodendroglial process dynamics and survival","volume":"55","author":"Miron","year":"2007","journal-title":"Glia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.2353\/ajpath.2009.080947","article-title":"Statin therapy inhibits remyelination in the central nervous system","volume":"174","author":"Miron","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(13)62242-4","article-title":"Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): A randomised, placebo-controlled, phase 2 trial","volume":"383","author":"Chataway","year":"2014","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e1729","DOI":"10.1212\/WNL.0000000000207777","article-title":"Exploring the Role of Plasma Lipids and Statin Interventions on Multiple Sclerosis Risk and Severity A Mendelian Randomization Study","volume":"101","author":"Almramhi","year":"2023","journal-title":"Neurology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1352458511421920","article-title":"Statin therapy and multiple sclerosis disability in a population-based cohort","volume":"18","author":"Pittock","year":"2012","journal-title":"Mult. Scler. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.4049\/jimmunol.0803563","article-title":"Metformin Attenuated the Autoimmune Disease of the Central Nervous System in Animal Models of Multiple Sclerosis","volume":"182","author":"Nath","year":"2009","journal-title":"J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jneuroim.2016.01.014","article-title":"Metformin ameliorates the development of experimental autoimmune encephalomyelitis by regulating T helper 17 and regulatory T cells in mice","volume":"292","author":"Sun","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"8126","DOI":"10.1038\/s41467-025-63279-4","article-title":"Metformin alters mitochondria-related metabolism and enhances human oligodendrocyte function","volume":"16","author":"Kazakou","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"148648","DOI":"10.1016\/j.brainres.2023.148648","article-title":"Metformin treatment reduces inflammation, dysmyelination and disease severity in a mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis","volume":"1822","author":"Gilbert","year":"2024","journal-title":"Brain Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"578852","DOI":"10.1016\/j.jneuroim.2025.578852","article-title":"Efficacy and tolerability of metformin as an adjuvant therapy in patients with relapse-remitting multiple sclerosis receiving interferon Beta 1a: A randomized pilot trial","volume":"412","author":"Abdelgaied","year":"2026","journal-title":"J. Neuroimmunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1007\/s00415-023-12113-2","article-title":"The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: An exploratory prospective phase II open-label randomized controlled trial","volume":"271","author":"Abdelgaied","year":"2024","journal-title":"J. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"De Keersmaecker, A.-V., Van Doninck, E., Popescu, V., Willem, L., Cambron, M., Laureys, G., Haeseleer, M.D., Bjerke, M., Roelant, E., and Lemmerling, M. (2024). A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): Study protocol for a multi-center randomized placebo controlled clinical trial. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1362629"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ajpath.2013.04.030","article-title":"AMP-Activated Protein Kinase Signaling Protects Oligodendrocytes that Restore Central Nervous System Functions in an Experimental Autoimmune Encephalomyelitis Model","volume":"183","author":"Paintlia","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/jamaneurol.2015.4807","article-title":"Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis","volume":"73","author":"Negrotto","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S1474-4422(19)30485-5","article-title":"Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): A phase 2b, multiarm, double-blind, randomised placebo-controlled trial","volume":"19","author":"Chataway","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"658520","DOI":"10.1155\/2008\/658520","article-title":"PPAR Regulation of Inflammatory Signaling in CNS Diseases","volume":"2008","author":"Bright","year":"2008","journal-title":"PPAR Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Vall\u00e9e, A., Lecarpentier, Y., Guillevin, R., and Vall\u00e9e, J.-N. (2018). Demyelination in multiple sclerosis: Reprogramming energy metabolism and potential PPAR\u03b3 agonist treatment approaches. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19041212"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Mondal, S., Sheinin, M., Rangasamy, S.B., and Pahan, K. (2024). Amelioration of experimental autoimmune encephalomyelitis by gemfibrozil in mice via PPAR\u03b2\/\u03b4: Implications for multiple sclerosis. Front. Cell. Neurosci., 18.","DOI":"10.3389\/fncel.2024.1375531"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41419-023-06260-7","article-title":"FKBP5 activates mitophagy by ablating PPAR-\u03b3 to shape a benign remyelination environment","volume":"14","author":"Sun","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/brain\/awae378","article-title":"Nuclear receptor PPAR\u03b3 targets GPNMB to promote oligodendrocyte development and remyelination","volume":"148","author":"Han","year":"2025","journal-title":"Brain"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s40001-024-01700-2","article-title":"Role of fenofibrate in multiple sclerosis","volume":"29","author":"Abulaban","year":"2024","journal-title":"Eur. J. Med Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/hmg\/ddv477","article-title":"Preferential PPAR-\u03b1 activation reduces neuroinflammation, and blocks neurodegeneration in vivo","volume":"25","author":"Esmaeili","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/j.1471-4159.2007.04875.x","article-title":"Peroxisome proliferator-activated receptor-\u03b1 agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: Relevance to multiple sclerosis","volume":"103","author":"Xu","year":"2007","journal-title":"J. Neurochem."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Schuldesz, A.C., Tudor, R., Nandarge, P.S., Elagez, A., Cornea, A., Ion, R., Bratosin, F., Prodan, M., and Simu, M. (2024). The Effects of Epigallocatechin-3-Gallate Nutritional Supplementation in the Management of Multiple Sclerosis: A Systematic Review of Clinical Trials. Nutrients, 16.","DOI":"10.3390\/nu16162723"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Payne, A., Nahashon, S., Taka, E., Adinew, G.M., and Soliman, K.F.A. (2022). Epigallocatechin-3-Gallate (EGCG): New Therapeutic Perspectives for Neuroprotection, Aging, and Neuroinflammation for the Modern Age. Biomolecules, 12.","DOI":"10.3390\/biom12030371"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Afzal, O., Dalhat, M.H., Altamimi, A.S.A., Rasool, R., Alzarea, S.I., Almalki, W.H., Murtaza, B.N., Iftikhar, S., Nadeem, S., and Nadeem, M.S. (2022). Green Tea Catechins Attenuate Neurodegenerative Diseases and Cognitive Deficits. Molecules, 27.","DOI":"10.3390\/molecules27217604"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.4049\/jimmunol.173.9.5794","article-title":"Green Tea Epigallocatechin-3-Gallate Mediates T Cellular NF-\u03baB Inhibition and Exerts Neuroprotection in Autoimmune Encephalomyelitis","volume":"173","author":"Aktas","year":"2004","journal-title":"J. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"de la Rubia Ort\u00ed, J.E., Armero, J.L.P., Cuerda-Ballester, M., Sanchis-Sanchis, C.E., Navarro-Illana, E., Lajara-Romance, J.M., Benlloch, M., Ceron, J.J., Tvarijonaviciute, A., and Proa\u00f1o, B. (2023). Lipid Profile in Multiple Sclerosis: Functional Capacity and Therapeutic Potential of Its Regulation after Intervention with Epigallocatechin Gallate and Coconut Oil. Foods, 12.","DOI":"10.3390\/foods12203730"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Klumbies, K., Rust, R., D\u00f6rr, J., Konietschke, F., Paul, F., Bellmann-Strobl, J., Brandt, A.U., and Zimmermann, H.G. (2021). Retinal Thickness Analysis in Progressive Multiple Sclerosis Patients Treated with Epigallocatechin Gallate: Optical Coherence Tomography Results from the SUPREMES Study. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.615790"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Platero, J.L., Cuerda-Ballester, M., Ib\u00e1\u00f1ez, V., Sancho, D., Lopez-Rodr\u00edguez, M.M., Drehmer, E., and Ort\u00ed, J.E.D.L.R. (2020). The impact of coconut oil and epigallocatechin gallate on the levels of il-6, anxiety and disability in multiple sclerosis patients. Nutrients, 12.","DOI":"10.3390\/nu12020305"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"104799","DOI":"10.1016\/j.msard.2023.104799","article-title":"What\u2019s your cup of tea? The role of herbal compounds in the management of multiple sclerosis","volume":"76","author":"Abdelgaied","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"10045","DOI":"10.1007\/s12035-025-04868-8","article-title":"Epigenetic and Mitochondrial Metabolic Dysfunction in Multiple Sclerosis: A Review of Herbal Drug Approaches and Current Clinical Trials","volume":"62","author":"Sharma","year":"2025","journal-title":"Mol. Neurobiol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Elbini-Dhouib, I., Manai, M., Neili, N.-E., Marzouki, S., Sahraoui, G., Ben Achour, W., Zouaghi, S., BenAhmed, M., Doghri, R., and Srairi-Abid, N. (2022). Dual Mechanism of Action of Curcumin in Experimental Models of Multiple Sclerosis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158658"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/cbf.3841","article-title":"Curcumin and targeting of molecular and metabolic pathways in multiple sclerosis","volume":"41","author":"Yazdani","year":"2023","journal-title":"Cell Biochem. Funct."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e70369","DOI":"10.1002\/jbt.70369","article-title":"Neuroprotective Potential of Curcumin in Neurodegenerative Diseases: Clinical Insights Into Cellular and Molecular Signaling Pathways","volume":"39","author":"Islam","year":"2025","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Guan, X., Wu, Y., Jia, Q., Zheng, Y., Zou, M., Liu, J., Sugimoto, K., and Gao, Y. (2025). Efficacy and safety of Chinese herbal medicine for multiple sclerosis: A systematic review and meta-analysis of randomized controlled trials. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1635833"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","article-title":"Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): A randomised, controlled, double-blind, crossover trial","volume":"390","author":"Green","year":"2017","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Amadio, S., Conte, F., Esposito, G., Fiscon, G., Paci, P., and Volont\u00e9, C. (2022). Repurposing Histaminergic Drugs in Multiple Sclerosis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23116347"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Kocot, J., Kosa, P., Ashida, S., Pirjanian, N.A., Goldbach-Mansky, R., Peterson, K., Fossati, V., Holland, S.M., and Bielekova, B. (2025). Clemastine fumarate accelerates accumulation of disability in progressive multiple sclerosis by enhancing pyroptosis. J. Clin. Investig., 135.","DOI":"10.1172\/JCI183941"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/nm.3618","article-title":"Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis","volume":"20","author":"Mei","year":"2014","journal-title":"Nat. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"111481","DOI":"10.1016\/j.intimp.2023.111481","article-title":"The preferential effect of Clemastine on F3\/Contactin-1\/Notch-1 compared to Jagged-1\/Notch-1 justifies its remyelinating effect in an experimental model of multiple sclerosis in rats","volume":"128","author":"Ibrahim","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jphs.2020.08.003","article-title":"Torsadogenic potential of a novel remyelinating drug clemastine for multiple sclerosis assessed in the rabbit proarrhythmia model","volume":"144","author":"Kawakami","year":"2020","journal-title":"J. Pharmacol. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Yamazaki, R., and Ohno, N. (2025). The potential of repurposing clemastine to promote remyelination. Front. Cell. Neurosci., 19.","DOI":"10.3389\/fncel.2025.1582902"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1186\/s13063-025-09254-2","article-title":"The Cambridge Centre for Myelin Repair trial Two (CCMR Two): A trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy","volume":"26","author":"McMurran","year":"2025","journal-title":"Trials"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"892","DOI":"10.21037\/atm.2020.03.131","article-title":"Opicinumab: Is it a potential treatment for multiple sclerosis?","volume":"8","author":"Ahmed","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1517\/14712598.8.10.1561","article-title":"LINGO-1 antagonists as therapy for multiple sclerosis: In vitro and in vivo evidence","volume":"8","author":"Rudick","year":"2008","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1212\/NXI.0000000000000018","article-title":"Randomized phase I trials of the safety\/tolerability of anti-LINGO-1 monoclonal antibody BIIB033","volume":"1","author":"Tran","year":"2014","journal-title":"Neuroimmunol. Neuroinflammation"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1474-4422(19)30137-1","article-title":"Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): A randomised, placebo-controlled, phase 2 trial","volume":"18","author":"Cadavid","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/13524585251396433","article-title":"Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial","volume":"32","author":"Calabresi","year":"2026","journal-title":"Mult. Scler. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11064-021-03465-0","article-title":"Clemastine Enhances Myelination, Delays Axonal Loss and Promotes Functional Recovery in Spinal Cord Injury","volume":"47","author":"Du","year":"2022","journal-title":"Neurochem. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/9\/3857\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:43:58Z","timestamp":1777376638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/9\/3857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":72,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ijms27093857"],"URL":"https:\/\/doi.org\/10.3390\/ijms27093857","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]}}}